pharma · Contraception · Chlamydia Trachomatis Infection · EVFM
Evofem Biosciences
Evofem Biosciences is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker EVFM. Primary therapeutic focus areas include Contraception, Chlamydia Trachomatis Infection, Sexually Transmitt
San Diego, USA HQ
2015 Founded
39 Employees
Public company Type
EVFM · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2015
- Employees
- 39
- Programs
- 6
- Drugs
- 2
- Patents
- 8
LIPO-202
Phase 3 · small molecule · Central Abdominal Bulging
LIPO-202 for Central Abdominal Bulging is a Phase 3 program (small_molecule) at Evofem Biosciences with 2 ClinicalTrials.gov record(s).
Internal code LIPO-202-CL-23
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Evofem Biosciences
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Central Abdominal Bulging
- Status
- terminated
- Trials
- 2